Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4830 + pembrolizumab + chemotherapy in high-grade serous ovarian cancer
NCT05446870Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 11
01
Overview
A Phase 2 trial of mk-4830 in high grade serous ovarian carcinoma (HGSC), sponsored by Merck & Co.. Started Jul 2022; status: completed.
02
Drugs
mk-4830
03
Conditions
high grade serous ovarian carcinoma (HGSC)
Beyond the preview
Go deeper on NCT05446870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446870.